Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1993-07-26
1999-08-24
Spector, Lorraine
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
530350, 935 9, C07H 2100, C07K 14705, C12N 1512
Patent
active
059426071
ABSTRACT:
Isolated nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the isolated nucleic acid has a sequence which encodes a B lymphocyte activation antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO: 1. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen.
REFERENCES:
D.J. Lenschow et al PNAS 90:11054-8 Dec. 1, 1993.
V.A. Boussiotis et al. PNAS 90:11059-63 Dec. 1, 1993.
G.J. Freeman et al. Science 262:909 Nov. 5, 1993.
S.O. Southern et al. J. Immunol. 142:336-342 Jan. 1, 1989.
Schwartz, "A Cell Culture Model for Lymphocyte Clonal Anergy" Science, vol. 248, pp, 1349-1356, (1990).
Reiser et al., "Murine B7 antigen provides an efficient costimulatory signal activation of murine T lymphocytes via T cell receptor/CD3 complex" Proceedings of the National Academy of Sciences, vol. 89, pp. 271-275, (1992).
Freeman et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7" Journal Experimental Medicine, vol. 174, pp. 625-631, (1991).
Gimmi et al., "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2" Proceedings of the National Academy of Sciences, vol. 88, pp. 6575-6579, (1991).
Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation" Journal Experimental Medicine, vol. 173, pp. 721-730, (1991).
Freeman et al., "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells" Journal of Immunology, vol. 143, No. 8, pp 2714-2722, (1989).
Thompson et al., "CD28 activation pathway regulates the production of multiple T-cell derived lymphokines/cytokines" Proceedings of the National Academy of Sciences, vol. 86, pp. 1333-1337, (1989).
Freedman et al., "B7, A B Cell-Restricted Antigen That Identifies Preactivated B Cells" Journal of Immunology, vol. 139, No. 10, pp. 3260-3267, (1987).
Freeman Gordon J.
Gray Gary S.
Nadler Lee M.
Dana-Farber Cancer Institute
Mandragouras Amy E.
Spector Lorraine
Williams Megan E.
LandOfFree
B7-2: a CTLA4/CD28 ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B7-2: a CTLA4/CD28 ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B7-2: a CTLA4/CD28 ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-467750